Verastem (VSTM) Misses Q1 EPS by 5c, Revenues Miss; FY19 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Verastem Oncology Reports First Quarter 2019 Financial Results
May 9, 2019 4:05 PM EDTCompany Reports $1.7 Million in Net Product Revenues from COPIKTRA; Issues Product Revenue Guidance for 2019
Cash, Cash Equivalents and Short-Term Investments of $211.7 Million as of March 31, 2019
Company to Host Conference Call Today at 4:30 PM ET
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology, (or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today reported financial results for the three months ended March 31, 2019.
We are now into the... More
